ELEV May 2024 2.500 call
| Previous close | 1.9000 |
| Open | 1.9000 |
| Bid | 0.0000 |
| Ask | 3.9000 |
| Strike | 2.50 |
| Expiry date | 2024-05-17 |
| Day's range | 1.9000 - 1.9000 |
| Contract range | N/A |
| Volume | |
| Open interest | 55 |
PR NewswireElevation Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Achievements
Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced financial results for the quarter ended March 31, 2024, and highlighted recent business achievements.
- PR Newswire
Elevation Oncology Presents Preclinical Proof-of-Concept Data for HER3-ADC Program at AACR Annual Meeting 2024
Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced new preclinical data demonstrating proof-of-concept for its differentiated HER3-ADC program. The data will be presented in a poster session at the American Association for Cancer Research (AACR) Annual Meeting 2024, being held April 5-10 in San Diego, Ca
- GuruFocus.com
Elevation Oncology Inc (ELEV) Reports Financial Results for Q4 and Full Year 2023
Strategic Advances Amidst Financial Prudence
